Xaar logo

XAR - Xaar News Story

42.9p -0.1  -0.2%

Last Trade - 27/02/20

Micro Cap
Market Cap £33.6m
Enterprise Value £16.8m
Revenue £50.7m
Position in Universe 1243rd / 1840

Xaar PLC - Completion of Investment by Stratasys in Xaar 3D

Wed 4th December, 2019 4:53pm
RNS Number : 7187V
Xaar PLC
04 December 2019


Xaar plc (the "Company")

Completion of Investment by Stratasys in Xaar 3D Limited


The Company is pleased to announce that following the announcement of 27 November 2019, the proposed increase of investment by Stratasys in Xaar 3D with an option for Stratasys to acquire the whole of Xaar 3D within 3 years, has completed following receipt of funds. 





Xaar plc

John Mills, Chief Executive Officer

Shomit Kenkare, Chief Financial Officer

+44 (0)1223 423 663 

Jefferies International (Financial advisor and Sponsor)

+44 (0)20 7029 8000

Max Jones

Will Soutar

Tulchan Communications

+44 (0)20 7353 4200

James Macey White




About Xaar
Xaar is a world leader in the development of digital inkjet technology. Our technology drives the conversion of analogue printing and manufacturing methods to digital inkjet which is more efficient, more economical and more productive than the traditional methods which have been in use for years. We design and manufacture printheads as well as systems for product decoration and 3D Printing which use our inkjet technology.


About Stratasys

Stratasys is a global leader in additive technology solutions for industries including Aerospace, Automotive, Healthcare, Consumer Products and Education. For nearly 30 years, a deep and ongoing focus on customers' business requirements has fueled purposeful innovations - 1,200 granted and pending additive technology patents to date - that create new value across product lifecycle processes, from design prototypes to manufacturing tools and final production parts.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.